Botanix Pharmaceuticals Ltd
Research Botanix Pharmaceuticals Ltd (BOT) on Bullrun: market cap AUD 54.69M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBOT
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 54.69M
- Financial periodFY2025
- RevenueAUD 5.76M
- Revenue growth856.6%
- Net income-AUD 86.40M
- Free cash flow-AUD 79.63M
- Gross margin40.3%
Valuation Snapshot
latest market cap is AUD 54.69M.
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers;
Frequently asked questions
What is Botanix Pharmaceuticals Ltd's market cap?
Botanix Pharmaceuticals Ltd's market capitalization is AUD 54.69M.
What does Botanix Pharmaceuticals Ltd do?
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age...